Drug targeting BRAF mutation slows thyroid cancer, too

Researchers found that treating metastatic thyroid cancer patients harboring a BRAF mutation with the targeted therapy vemurafenib — originally approved for melanoma patients with the mutation — showed promising anti-tumor activity in a third of patients.